Objective: To determine if enteral protein and energy supplementation would significantly improve weight gain as compared with energy supplementation alone in p1250 g infants.
Introduction
Nutritional management of the very low birth weight (VLBW) and the extremely low birth weight infant has proven to be very challenging for today's neonatal intensive care unit health care team. The discharge weight of most VLBW infants remains below the 10th percentile of reference intrauterine weights leading to postnatal growth restriction. [1] [2] [3] Poor neonatal weight gain and head growth have been linked to significant neurodevelopmental outcomes. [4] [5] [6] To achieve the necessary catch-up growth, nutritional supplements have been added to standard preterm formula or fortified human milk. These supplements include carbohydrate, fat, protein or some combination. [7] [8] [9] [10] [11] [12] [13] To increase dietary caloric density of the enteral diet, the most common method in our unit is with energy supplementation in the form of medium chain triglyceride oil (MCT). Use of MCT remains the most common practice on a national level as reflected by the recently published results of the 2006 Neonatal Nutrition Survey such that 74% of respondents used MCT as an additive to formula. 13 However, several clinical trials examining protein-enriched formulas for low birth weight infants have shown improved growth with higher concentrations of protein. [14] [15] [16] Therefore, we chose to study the effect of energy supplementation on growth compared with the effect of a multinutrient supplement that provided increased protein and energy intake in smaller infants with birth weights (BWs) p1250 g. We hypothesized that the nutritional intervention of a combined protein and energy supplement would support better in-hospital growth than energy supplementation alone in infants with a BW p1250 g. A randomized non-masked trial including both human-milk-and formula-fed infants was undertaken to assess the nutritional intervention of protein and energy as compared with energy alone for those VLBW infants who were growing below the average intrauterine rate of 15 g kg À1 per day 17 or who had failed to regain BW in the first 2 weeks of life.
Methods
Infants were eligible if they had a BW p1250 g, postnatal age of at least 14 days, nutritional support in which at least 75% was provided by enteral nutrition (fortified human milk, formula or a combination), and either failure to regain BW by 14 days of age or weight gain less than 15 g kg À1 per day after having regained BW. Infants were excluded if they had a major congenital malformation, suspected or confirmed necrotizing enterocolitis (NEC), conditions that required major surgery, intrauterine infections that impede growth or genetic diseases that result in growth failure.
A total of 63 infants with a BW of 1250 g or less were screened at the Newborn Special Care Unit, Yale-New Haven Children's Hospital from 1 July 2001 to 31 January 2002. Of the 63 infants, 30 were determined to be eligible, and 33 infants were excluded based on adequate growth (n ¼ 4), transfer to an outside hospital before qualification (n ¼ 6), death (n ¼ 8), major congenital malformations (n ¼ 2) or NEC (n ¼ 13). A total of 23 VLBW infants were randomized after parental consent was obtained; 22 for slow growth and 1 for failure to regain BW by 14 days of age. Twelve infants were randomized to receive the energy-alone supplement (MCT; Mead Johnson Nutritionals, Evansville, IN, USA), of which the baseline diet for five was fortified human milk, for five was formula and for two was a combination of formula and fortified human milk. Eleven infants were randomized to receive a multinutrient supplement providing protein and energy (P/E; in the form of powdered Enfamil EnfaCare (Mead Johnson Nutritionals), of which the baseline diet for four was fortified human milk, for four formula, and for three a combination of formula and fortified human milk.
The shortest period of time an infant spent in the study was 8 days. This study was approved by the Yale University Human Investigation Committee.
Randomization was carried out in blocks of six and stratified into three BW groups (<750 g, 751 to 1000 g and 1001 to 1250 g). The study was not masked as MCT (oil) and P/E (powder) are easily discernable from one another. Infants with a baseline diet of human milk were already receiving human milk fortified with human milk fortifier (Enfamil Human Milk Fortifier; Mead Johnson Nutritionals) before study initiation. Formula-fed infants received a proprietary preterm formula (Enfamil Premature, 24 calories per 30 ml; Mead Johnson Nutritionals).
Those infants randomized to the energy-alone intervention received MCT at a dosage of 2 ml kg À1 per day divided into four equivalent doses a day that were adjusted weekly for each infant's current weight. The maximum allowable MCT dose for the study was 3 ml per day. The infants randomized to the multinutrient intervention received as per standard nursing protocol a 1/4 teaspoon of powdered P/E per 30 ml of either fortified human milk or premature formula. The two interventions were designed to be isocaloric.
The caloric density and protein content of each infant's net intake from both enteral and parenteral nutrition were calculated. Nutritional data were recorded daily for the 4-week study period. Nutritional content of P/E supplementation is based on Mead Johnson Nutritionals product information and summarized in Table 1 . MCT oil was estimated to contain 7.7 kcal per ml (Mead Johnson Nutritionals). Medium chain triglycerides are unique as a fat supplement in that they are oxidized allowing for a rapidly available source of energy, but only minimally contribute to fat deposition. 18 The primary outcome of growth was measured during the 4-week study period by daily weights and weekly lengths, head circumferences and mid-arm circumferences (midpoint of the humerus). 1 Rate of weight gain (g kg À1 per day) was calculated by subtracting the initial study weight from the final study weight, dividing this number by days elapsed (g per day) and then dividing the g per day by the average body weight during the study period. In addition to mean discharge weight comparisons, each infant's discharge weight was compared with 10th percentile reference intrauterine values. 19 Data were also recorded about baseline characteristics and the occurrence of other clinical outcomes during the entire hospital stay, including days of oxygen therapy, mechanical ventilation, nasal continuous positive airway pressure and age (days) at discharge or death. The incidence of a number of neonatal morbidities such as NEC, 20 cholestatic jaundice, late onset sepsis, bronchopulmonary dysplasia (BPD), grade 3 or 4 intraventricular hemorrhage 21 and periventricular leukomalacia were recorded and compared between groups. Late onset sepsis was defined as either a positive blood culture with clinical symptoms or a negative culture with symptoms and treatment with antibiotics for 5 or more days 1 in an infant who is at least 7 days of age. 22 BPD was first defined as treatment with oxygen (>21%) for at least 28 days and then categorized as mild, moderate or severe as recently described. 23 Statistical analysis was based on intent to treat over the 4-week study period. Statistical Analysis Software (version 8.0; SAS Inc., Cary, NC, USA) was used for data analysis. Statistical significance was attributed to P-values less than 0.05. Bivariate analysis was based on intent to treat and a secondary analysis on protein intake. For categorical data, the w 2 -test or Fisher's exact test was used when indicated. The two-tailed t-test was used for continuous data, and data are reported as mean±s.d. Initial sample size calculation was based on data extrapolated from Ehrenkranz et al. 1 related to the age that BW was regained. We estimated a sample size of 24 infants, with 12 in each group, to detect a 1-week decrease in time for those not regaining BW by 14 days of age, assuming a ¼ 0.05 and a power of 80%. However, the majority of patients were enrolled for poor growth, not as expected based on failure to regain BW by 14 days. In addition, because of study personnel changes, study enrollment was discontinued early.
Results
A total of 23 infants were enrolled; 12 infants were randomized to the energy-alone intervention (MCT group) and 11 were randomized to the protein and energy intervention (P/E group). BW, gestational age and other baseline characteristics or characteristics during the 4-week study period did not differ significantly between the two groups ( Table 2 ). There were no differences in the numbers of small for gestational age infants or in the gender or race distribution between the two groups. Consistent with the intended intervention, mean caloric intakes were similar, whereas mean protein intakes were significantly higher in the P/E group (protein intake: MCT ¼ 3.0 ± 0.5 g kg À1 per day, P/E ¼ 3.5±0.3 g kg À1 per day, P<0.01). The infants receiving P/E grew significantly better than those receiving the energy-alone intervention (Table 2) . Infants randomized to receive MCT (n ¼ 12) gained 11.5 ± 4.8 g kg À1 per day (Table 2 ) whereas those randomized to P/E (n ¼ 11) gained 17.0±2.4 g kg À1 per day (P<0.01). Other anthropometric measurements (Table 2) show a similar trend, but weekly measurements were not always available, as some infants were critically ill. Head circumference and mid-arm circumference increased significantly (Ps<0.05) more in the P/E group, and although length gain was not significantly different, the trend was similar. Analysis of data was a priori performed by intent. All infants received the intervention to which they were randomized. However, one infant in addition to receiving P/E did receive 5 days of MCT during the third study week. Regardless of treatment group, it was found that protein intake (g k À1 per day) was significantly correlated with (r 2 ¼ 0.53, P<0.001) weight gain (g k À1 per day). The average discharge weights were not significantly different (data are shown in Table 2 ). When comparing the discharge weights with the 10th percentile reference growth curves, 19 there were no differences between the two groups; seven study infants (three in MCT group and four in P/E group) remained above the 19 Therefore, although the rate of weight gain in the infants receiving P/E exceeded the intrauterine rate of 15 g kg À1 per day, most of these infants did not catch up adequately.
Although the study was planned for 4 weeks, the mean duration was 23±7 days in the MCT group compared to 22±8 days in the P/E group (NS). Infants remained in the study for less than 4 weeks due to discharge to home (n ¼ 6; two in MCT group and four in P/E group, NS), transfer to another hospital (n ¼ 1, MCT group) or withdrawal from study (n ¼ 3; two in MCT group and one in P/E group). Of the infants withdrawn, one infant had cytomegalovirus colitis (P/E group), one was diagnosed with milk protein intolerance (MCT group) and one infant with NEC and pseudomonas sepsis (MCT group). The infant with NEC was the only infant in the study who died. Data from these three infants obtained before study interruption are included in the analysis. Another infant (receiving P/E supplement) was diagnosed with NEC after completing the 28-day study period.
There was no difference between the groups regarding stool quality, stool number, presence of occult or gross blood in stool, abdominal distension, acidosis, gastric aspirates or emesis. As mentioned previously, one infant from each group was diagnosed with NEC. The laboratory values that were obtained for clinical reasons during the study were not significantly different. During the entire period of hospital stay, the measured clinical outcomes did not differ between the MCT and the P/E groups. The mean length of stay, number of days of oxygen therapy, ventilation and nasal continuous positive airway pressure did not significantly differ. There was no significant difference in the number of infants who received postnatal steroids or diuretic therapy for BPD between the MCT group (steroids n ¼ 5, diuretics n ¼ 7) and the P/E group (steroids n ¼ 2, diuretics n ¼ 7, P's>0.05). The incidence of cholestatic jaundice, BPD and late onset sepsis was not significantly different. There were no cases of intraventricular hemorrhages (grade 3 or 4) or periventricular leukomalacia in either group of infants (Table 2) .
Discussion
This study showed improved in-hospital growth of VLBW infants receiving caloric supplementation in the form of a multinutrient supplement that provided both protein and energy (P/E) compared with a supplement that provided energy alone (MCT). Analysis by intent to treat showed that weight gain, head circumference gain, and mid-arm circumference gain were significantly better in the P/E group than in the MCT group. In addition, length gain, although not statistically significant, did follow the trend of the other growth parameters. Furthermore, the impact of added protein on growth was shown with protein being highly correlated with weight gain regardless of intervention group. The difference in weight gain between the two groups was likely due to the fact that in addition to the significance of protein, MCT contributed very little to fat deposition, and is more of a source for rapidly accessible energy. 18 Our findings of the importance of the type of calories supplied for in-hospital preterm growth have been emphasized by other investigators. [14] [15] [16] [24] [25] [26] [27] [28] [29] [30] In 1998, Carlson and Zeigler 24 published a longitudinal study of 51 preterm infants and their protein intake, energy intake and subsequent growth. Regression analysis suggested that protein intake related positively to growth. Olsen et al. 25 showed an association between increased protein intake and improved growth velocity in regression analysis of a cohort consisting infants from six neonatal intensive care units. Embleton and Cooke 16 also found that discharge weight, length and head circumference were significantly related to higher proteincontaining formulas. Furthermore, our observation that the protein intake of 3.5 g kg À1 per day in our P/E group, which was associated with improved postnatal growth, is consistent with the published literature. [14] [15] [16] 25, 26 Our study was limited by the small number of infants enrolled, but, as significant differences in growth are seen despite the limited number of infants, we believe that this observation is clinically significant. Nevertheless, it is possible with a larger sample size that growth rates would not have differed between groups or that days on steroids would be significantly different between groups. Owing to the small numbers, no corrections were carried out for postnatal steroid or diuretic exposure for BPD. However, it is important to note that these results are consistent with a growing body of literature highlighting the importance of protein supplementation in VLBW infants. [14] [15] [16] 25, 26 Another important limitation to this study was that the fortified human milk, premature formula, and combination of fortified human milk and premature formula-fed infants were grouped together for analysis by intent. Furthermore, we acknowledge that our estimates of protein intake in patients receiving fortified human milk (Table 1 ) may differ from actual intake. 31 However, as there were no differences in the distribution of the baseline diets between the MCT and P/E groups, it is unlikely that our results were affected. In addition, the identity of the two nutritional interventions could not be hidden from the clinical team that cared for the infants because the difference between the nutritional supplements (an oil versus a powder) was obvious. The knowledge of the specific nutritional supplement that each infant received, however, is unlikely to have impacted objective measurements such as daily weight, other anthropometric measurements, laboratory values, or changes in gastric residuals or stool patterns. Despite the demonstration of better growth in most parameters, body composition studies were not performed to confirm whether weight gain was merely fat deposition. Because all anthropometric measurements in this study (including length) trended in the same direction, we surmise that the weight gain observed was not just fatty tissue deposition.
Although this and other studies have determined the importance of protein, MCT still remains the most common additive to formula according to the results of the 2006 Neonatal Nutrition Survey. 13 Even more surprising is the fact that respondents used MCT more frequently at academic centers as opposed to private and public sites. 13 Interestingly, the survey results showed that significantly more dieticians as opposed to physicians add protein powder to either human milk or formula. 13 This survey highlights the continued need for raising practitioner awareness of the role of enteral protein and growth in VLBW infants. To improve growth in these infants, supplementation of protein must be considered by a team approach that includes dietician involvement. Identifying a P/E supplement that could be administered with a variety of enteral diets to increase weight gain would be useful for the practitioner caring for VLBW infants with poor in-hospital growth. This study has shown the growth benefits of increasing caloric intake with a multinutrient supplement that provides both protein and energy compared with a supplement that provides only energy.
